Misely L, et al2
|
21 |
Male |
None |
Bacillus Calmette-Guérin |
First |
30 days after vaccination |
Urticarial eruption |
Upper limbs |
Fever and polyarthralgia |
Hyperleukocytosis and lowered C4 level |
24 weeks |
None |
Velasco-Tamariz V, et al3
|
6 |
Female |
None |
Serogroup B meningococcal |
First |
7 days after vaccination |
Annular and arciform urticarial wheals |
Lower limbs |
None |
None |
2 weeks |
Antihistamines |
Hughes R, et al4
|
21 |
Female |
None |
Influenza |
Unknown |
6 days after vaccination |
Urticarial plaques |
Trunk |
None |
None |
2 weeks |
Antihistamines |
Ono H, et al5
|
68 |
Male |
Diabetes mellitus, and hyperlipidemia |
COVID-19 |
Third |
4 days after vaccination |
Edematous erythema |
Trunk and extremities |
Fever and polyarthralgia |
Hyperleukocytosis and elevated C-reactive protein |
1 week |
Oral prednisone and antihistamines |
Baraldi C, et al6
|
78 |
Female |
None |
COVID-19 |
First |
7 days after vaccination |
Urticarial rash |
Extremities |
None |
None |
4 weeks |
Oral prednisone |
Nazzaro G, et al7
|
27 |
Female |
None |
COVID-19 |
First |
10 days after vaccination |
Erythematous wheals |
Trunk and extremities |
None |
None |
8 weeks |
Oral prednisone and antihistamines |
Dash S, et al8
|
27 |
Male |
None |
COVID-19 |
Second |
1 day after vaccination |
Urticarial plaques |
Trunk and extremities |
None |
Elevated C-reactive protein level |
1 week |
Oral indomethacin and antihistamines |
Daldoul M, et al9
|
73 |
Male |
Chronic urticaria |
COVID-19 |
Second |
2 days after vaccination |
Purpuric and reticulated plaques |
Trunk and extremities |
None |
Hyperleukocytosis and elevated C-reactive protein level |
1 week |
None |
Larson V, et al10
|
35 |
Female |
None |
COVID-19 |
First |
1 day after vaccination |
Erythematous and edematous plaques |
Trunk and extremities |
None |
Unknown |
Unknown |
Oral prednisone, dapsone, and antihistamines |
Tihy H, et al11
|
73 |
Male |
None |
COVID-19 |
Second |
21 days after vaccination |
Papules and urticarial plaques |
Trunk |
None |
Unknown |
Unknown |
Unknown |
Holmes GA, et al12
|
86 |
Female |
None |
COVID-19 |
Second |
5 days after vaccination |
Purpuric rash |
Face, trunk and extremities |
None |
None |
2 weeks |
Oral prednisone and antihistamines |
Imamura N, et al13
|
61 |
Male |
None |
COVID-19 |
First |
14 days after vaccination |
Purpura and urticaria-like rash |
Extremities |
Fever, polyarthralgia, and swollen lymph nodes |
Pancytopenia, increase in ferritin and C-reactive protein level, and decrease in CH50, C3, and C4 levels |
More than 40 weeks |
Steroid pulse with tapered oral prednisone, and oral cyclosporine |
Our case |
67 |
Female |
None |
Influenza |
More than five times |
3 days after vaccination |
Purpura and urticaria-like rash |
Trunk and extremities |
None |
Elevated C-reactive protein, D-dimer, and anticardiolipin antibody level |
12 weeks |
Antihistamines |